Paul F. Lizzul Sells 1,500 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now owns 11,618 shares in the company, valued at approximately $406,630. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

AnaptysBio Trading Down 2.2 %

Shares of AnaptysBio stock opened at $33.70 on Monday. The firm has a market capitalization of $920.68 million, a P/E ratio of -5.49 and a beta of -0.25. The business’s fifty day simple moving average is $25.51 and its 200 day simple moving average is $24.06. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $37.28.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.10). The firm had revenue of $7.18 million during the quarter, compared to the consensus estimate of $4.55 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. Analysts predict that AnaptysBio, Inc. will post -6.04 EPS for the current fiscal year.

Institutional Trading of AnaptysBio

Several hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 2,390 shares in the last quarter. Quest Partners LLC purchased a new position in AnaptysBio in the 4th quarter valued at approximately $119,000. SG Americas Securities LLC bought a new stake in AnaptysBio during the 4th quarter valued at $126,000. Finally, Virtu Financial LLC purchased a new stake in shares of AnaptysBio during the first quarter worth $222,000.

Analyst Ratings Changes

ANAB has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of AnaptysBio in a report on Friday, May 10th. SVB Leerink started coverage on AnaptysBio in a report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price on the stock. JPMorgan Chase & Co. upgraded AnaptysBio from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $29.00 to $69.00 in a report on Friday. Wells Fargo & Company started coverage on AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.50.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.